SCHEMBL5404296

SCHEMBL5404296

CCOP(=O)(OCC)C(CC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
POLB P06746 1/20 0.35
CYP2D6 P10635 1/20 0.35
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
HMGCR P04035 2/20 0.33
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
MAPT P10636 1/20 0.31
MLYCD O95822 5/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1984906 0.86 ALDH1A1 (0.41) GAACYP3A4CYP2C9CYP2C19POLB
SCHEMBL30459970 0.81 ALDH1A1 (0.49) GAACYP3A4CYP2C9CYP2C19POLB
SCHEMBL3311718 0.81 HMGCR (0.41) GAACYP3A4CYP2C9CYP2C19POLB
SCHEMBL25801646 0.79 ALDH1A1 (0.41) GAACYP3A4CYP2C9CYP2C19POLB
SCHEMBL14561060 0.79 POLB (0.41) GAACYP3A4CYP2C9CYP2C19POLB
SCHEMBL30050578 0.78 GAA (0.38) GAACYP3A4CYP2C9CYP2C19POLB
SCHEMBL6819825 0.77 GAA (0.36) GAACYP3A4CYP2C9CYP2C19POLB
SCHEMBL25801739 0.76 GAA (0.33) GAACYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL11801523 0.75 POLB (0.43) GAACYP3A4CYP2C9CYP2C19POLB
SCHEMBL262483 0.75 POLB (0.43) GAACYP3A4CYP2C9CYP2C19POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030119807-A1 3-Heterocyclylpropanohydroxamic acids BAILEY SIMON (US) 2003-06-26 US claimed
JP-2003519133-A 2003-06-17 JP claimed
EP-1240152-A1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS Pfizer Limited (GB) 2002-09-18 EP claimed
US-20010021718-A1 Procollagen C-proteinase inhibitors PFIZER INC. 2001-09-13 US claimed
WO-2001047901-A1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LIMITED (GB) 2001-07-05 WO claimed
US-7214694-B2 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors PFIZER INC (US) 2007-05-08 US disclosed
US-7214694-B2 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors PFIZER INC (US) 2007-05-08 US disclosed
US-7214694-B2 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors PFIZER INC (US) 2007-05-08 US disclosed
EP-1343771-B1 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LTD (GB) 2006-04-12 EP disclosed
EP-1373231-B1 3-HETEROCYCLYL-PROPANO-HYDROXAMIC ACID AS PCP INHIBITORS PFIZER LTD (GB) 2005-06-08 EP disclosed
EP-1199301-B1 Olefination process to itaconate and succinate derivatives PFIZER LTD (GB) 2005-06-08 EP disclosed
US-6897306-B2 3-heterocyclylpropanohydroxamic acids PFIZER PRODUCTS, INC. (US) 2005-05-24 US disclosed
EP-1240152-A1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS Pfizer Limited (GB) 2002-09-18 EP disclosed
US-6452041-B1 REACTING ALDEHYDE OF FORMULA RCHO, OR A PROTECTED DERIVATIVE THEREOF SUCH AS A HEMIACETAL OR ADDUCT THEREOF SUCH AS A BISULPHITE, WITH A PHOSPHORUS COMPOUND TO OBTAIN SUCCINATE OR ITACONATE DERIVATIVE PFIZER INC. 2002-09-17 US disclosed
US-6448278-B2 ANTISCARRING AGENT PFIZER INC. 2002-09-10 US disclosed
WO-2002050046-A1 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LIMITED (GB) 2002-06-27 WO disclosed
US-20020058832-A1 Novel olefination process to itaconate and succinate derivatives PFIZER INC. 2002-05-16 US disclosed
EP-1199301-A1 Olefination process to itaconate and succinate derivatives Pfizer Limited (GB) 2002-04-24 EP disclosed
US-20010021718-A1 Procollagen C-proteinase inhibitors PFIZER INC. 2001-09-13 US disclosed
WO-2001047901-A1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LIMITED (GB) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010021718-A1 Procollagen C-proteinase inhibitors MMP1, CTSL, PREP GAA 1264/4885CYP3A4 491/4885CYP2C9 559/4885
US-20020058832-A1 Novel olefination process to itaconate and succinate derivatives HOGA1, HADHA, OGDH GAA 1848/4885CYP3A4 219/4885CYP2C9 454/4885
US-20030119807-A1 3-Heterocyclylpropanohydroxamic acids CPA1, MMP1, PREP GAA 887/4885CYP3A4 195/4885CYP2C9 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.